Back to search
Post-viral Anosmia
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Post-viral Anosmia trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Post-viral Anosmia trials you may qualify forInvestigation of the mechanisms of persistent SARS-CoV-2 associated olfactory dysfunction (OD) in patients with well-documented olfactory function. The investig…
Persistent smell loss that can include diminished or distorted smell function is a common symptom of long COVID syndrome. There are limited treatment options fo…
Olfactory dysfunction is a defining symptom of COVID-19 infection. Studies have demonstrated improved olfaction in patients with post infectious olfactory dysfu…
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis, affecting up to 1.2 million people in t…
This is a phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy of topical intranasal treatment of beclomethasone vs. placebo f…
The purpose of this study is to learn more about how to better track smell recovery in people who have been infected with the SARS-CoV-2 virus (which causes COV…
Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.